You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Early trials give conflicting results on remdesivir to treat COVID-19, though a large trial suggests it shortens disease length, Nature News reports.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Two experimental drugs were unable to slow or prevent Alzheimer's disease among people at high genetic risk, the Associated Press reports.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
New Scientist reports that cancer patients treated with immune cells that underwent CRISPR-based gene editing exhibited no serious side effects.
The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
An analysis by Science finds that many institutes have not uploaded results to ClinicalTrials.gov within the one-year deadline.
With the participation of five cancer centers and clinics, Taproot is hoping to build a national, prospective data registry that is much needed but has been difficult to advance to date.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.